Albert David Shareholders Approve Dr. Rajiv Anant Desai's Appointment as Independent Director

Albert David , a prominent pharmaceutical company, has successfully appointed Dr. Rajiv Anant Desai as an Independent Director following overwhelming shareholder approval through a postal ballot. The special resolution for Dr. Desai's appointment received near-unanimous support, with 99.99% of votes cast in favor.

Appointment Details

Dr. Rajiv Anant Desai will serve as an Independent Director for a five-year term, commencing from August 2, 2025, to August 1, 2030. The appointment was approved through a postal ballot process, which included electronic voting (e-voting) to ensure wide participation and adherence to corporate governance norms.

Voting Process and Participation

The e-voting process for the postal ballot ran from August 18 to September 16, 2025. Out of the total 15,227 shareholders on record, 135 participated in the voting process. The breakdown of voting results is as follows:

Category	Votes in Favor	Votes Against	% in Favor
Promoter & Promoter Group	3,551,958	0	100.00%
Public - Institutional	118,491	0	100.00%
Public - Non-Institutional	9,759	471	95.40%
Total	3,680,208	471	99.99%

The special resolution was passed with an overwhelming majority, demonstrating strong shareholder confidence in Dr. Desai's appointment.

Dr. Rajiv Anant Desai's Profile

Dr. Desai brings a wealth of experience and expertise to Albert David. His qualifications include:

M.Sc. in Chemistry from Mumbai University
Ph.D. in Pharmaceutical Chemistry from ICT Mumbai Institute of Chemical Technology
MBA from NMIMS, Mumbai

With over 38 years of experience in the pharmaceutical industry, both in India and Switzerland, Dr. Desai has an impressive track record. He previously served as Executive Vice President, Global Corporate Quality at Lupin Limited until June 2022. Currently, he works as a Senior Technical Advisor with the Indian Pharmaceutical Alliance.

Company's Statement

Lalit Lohia, Company Secretary & Compliance Officer of Albert David, confirmed the appointment in a statement to the stock exchanges. The company emphasized that Dr. Desai is not related to any Director or Key Managerial Personnel of Albert David and is not debarred from holding the office of Director by any regulatory authority.

The appointment of Dr. Rajiv Anant Desai as an Independent Director is expected to bring valuable insights and expertise to Albert David's board, potentially contributing to the company's growth and governance in the coming years.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.96%	-2.43%	-12.01%	-3.35%	-43.82%	+71.69%

Albert David , a prominent pharmaceutical company, has released its unaudited financial results for the first quarter ended June 30, 2025, revealing a mixed performance compared to the same period last year.

Revenue Decline

The company reported total income from operations of Rs. 7,056.64 lakhs for Q1 FY2026, marking a significant decrease from Rs. 8,935.64 lakhs in Q1 FY2025. This represents a year-on-year decline of approximately 21.00% in revenue.

Profit Margins Under Pressure

Net profit for the quarter stood at Rs. 793.76 lakhs, down from Rs. 1,884.44 lakhs in the corresponding quarter of the previous year, indicating a substantial drop of about 58.00% in profitability.

Earnings Per Share

The company's basic and diluted earnings per share (EPS) for Q1 FY2026 were Rs. 13.91, compared to Rs. 33.02 in Q1 FY2025, reflecting the impact of reduced profitability on shareholder returns.

Financial Position

Albert David maintained its equity share capital at Rs. 570.72 lakhs, unchanged from the previous year.

Management Review

The financial results were reviewed by the audit committee and subsequently approved by the board of directors on August 2, 2025. The company's statutory auditors have conducted a limited review of these results as required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Segment Information

The company operates in the pharmaceutical products sector and has only one reportable segment in accordance with Ind AS-108 "Operating Segments".

Conclusion

While Albert David has faced challenges in the first quarter, it's important to note that quarterly results can be subject to various factors and may not necessarily indicate long-term trends. Investors and stakeholders will likely be watching closely to see how the company adapts to the current market conditions and works to improve its performance in the coming quarters.